Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines

Wojciech Feleszko; Ahmad Jalili; Dominika Olszewska; Izabela Mlynarczuk; Tomasz Grzela; Adam Giermasz; Marek Jakóbisiak

Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines

Wojciech Feleszko, Ahmad Jalili, Dominika Olszewska, Izabela Mlynarczuk, Tomasz Grzela, Adam Giermasz, Marek Jakóbisiak

Research output: Contribution to journal › Article › peer-review

Abstract

Statins, anti-hypercholesterolemic agents, have previously been reported to induce apoptosis and exert antitumor activity when combined with other antitumor agents. The potential of lovastatin in combination with highly specific COX-2 inhibitor (MF-tricyclic) to induce antiproliferative activity against tumour cells was evaluated using the combination index (CI) method. Murine colorectal cancer (colon-26, CMT-93), melanoma (B16F10) and human bladder carcinoma cells (T24) were tested. Exposure of colon-26 and CMT-93 cells resulted in synergistic interactions in both cell lines with CI<1 for 20-80% inhibition of cell growth in both cell lines. This synergy was not observed in the B16F10 melanoma and T24 bladder carcinoma cells. MF-tricyclic (40 μg/ml), augmented lovastatin-induced apoptosis up to 2.5-fold in colon-26 cancer cells. Combination of a specific COX-2 inhibitor, MF-tricyclic, may increase antiproliferative effects of lovastatin in colon cancer cells and this effect was due to an augmented apoptosis.

Original language	English (US)
Pages (from-to)	879-885
Number of pages	7
Journal	Oncology Reports
Volume	9
Issue number	4
State	Published - Jul 2002
Externally published	Yes

Keywords

Apoptosis
Colorectal cancer
COX-2 inhibitors
Lovastatin
Synergism

ASJC Scopus subject areas

Cancer Research
Oncology

Fingerprint Dive into the research topics of 'Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines'. Together they form a unique fingerprint.

Cite this

Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines. / Feleszko, Wojciech; Jalili, Ahmad; Olszewska, Dominika; Mlynarczuk, Izabela; Grzela, Tomasz; Giermasz, Adam; Jakóbisiak, Marek.

In: Oncology Reports, Vol. 9, No. 4, 07.2002, p. 879-885.

Research output: Contribution to journal › Article › peer-review

@article{181a18a304264436bd508b68a3c4d152,

title = "Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines",

abstract = "Statins, anti-hypercholesterolemic agents, have previously been reported to induce apoptosis and exert antitumor activity when combined with other antitumor agents. The potential of lovastatin in combination with highly specific COX-2 inhibitor (MF-tricyclic) to induce antiproliferative activity against tumour cells was evaluated using the combination index (CI) method. Murine colorectal cancer (colon-26, CMT-93), melanoma (B16F10) and human bladder carcinoma cells (T24) were tested. Exposure of colon-26 and CMT-93 cells resulted in synergistic interactions in both cell lines with CI<1 for 20-80% inhibition of cell growth in both cell lines. This synergy was not observed in the B16F10 melanoma and T24 bladder carcinoma cells. MF-tricyclic (40 μg/ml), augmented lovastatin-induced apoptosis up to 2.5-fold in colon-26 cancer cells. Combination of a specific COX-2 inhibitor, MF-tricyclic, may increase antiproliferative effects of lovastatin in colon cancer cells and this effect was due to an augmented apoptosis.",

keywords = "Apoptosis, Colorectal cancer, COX-2 inhibitors, Lovastatin, Synergism",

author = "Wojciech Feleszko and Ahmad Jalili and Dominika Olszewska and Izabela Mlynarczuk and Tomasz Grzela and Adam Giermasz and Marek Jak{\'o}bisiak",

year = "2002",

month = jul,

language = "English (US)",

volume = "9",

pages = "879--885",

journal = "Oncology Reports",

issn = "1021-335X",

publisher = "Spandidos Publications",

number = "4",

}

TY - JOUR

T1 - Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines

AU - Feleszko, Wojciech

AU - Jalili, Ahmad

AU - Olszewska, Dominika

AU - Mlynarczuk, Izabela

AU - Grzela, Tomasz

AU - Giermasz, Adam

AU - Jakóbisiak, Marek

PY - 2002/7

Y1 - 2002/7

N2 - Statins, anti-hypercholesterolemic agents, have previously been reported to induce apoptosis and exert antitumor activity when combined with other antitumor agents. The potential of lovastatin in combination with highly specific COX-2 inhibitor (MF-tricyclic) to induce antiproliferative activity against tumour cells was evaluated using the combination index (CI) method. Murine colorectal cancer (colon-26, CMT-93), melanoma (B16F10) and human bladder carcinoma cells (T24) were tested. Exposure of colon-26 and CMT-93 cells resulted in synergistic interactions in both cell lines with CI<1 for 20-80% inhibition of cell growth in both cell lines. This synergy was not observed in the B16F10 melanoma and T24 bladder carcinoma cells. MF-tricyclic (40 μg/ml), augmented lovastatin-induced apoptosis up to 2.5-fold in colon-26 cancer cells. Combination of a specific COX-2 inhibitor, MF-tricyclic, may increase antiproliferative effects of lovastatin in colon cancer cells and this effect was due to an augmented apoptosis.

AB - Statins, anti-hypercholesterolemic agents, have previously been reported to induce apoptosis and exert antitumor activity when combined with other antitumor agents. The potential of lovastatin in combination with highly specific COX-2 inhibitor (MF-tricyclic) to induce antiproliferative activity against tumour cells was evaluated using the combination index (CI) method. Murine colorectal cancer (colon-26, CMT-93), melanoma (B16F10) and human bladder carcinoma cells (T24) were tested. Exposure of colon-26 and CMT-93 cells resulted in synergistic interactions in both cell lines with CI<1 for 20-80% inhibition of cell growth in both cell lines. This synergy was not observed in the B16F10 melanoma and T24 bladder carcinoma cells. MF-tricyclic (40 μg/ml), augmented lovastatin-induced apoptosis up to 2.5-fold in colon-26 cancer cells. Combination of a specific COX-2 inhibitor, MF-tricyclic, may increase antiproliferative effects of lovastatin in colon cancer cells and this effect was due to an augmented apoptosis.

KW - Apoptosis

KW - Colorectal cancer

KW - COX-2 inhibitors

KW - Lovastatin

KW - Synergism

UR - http://www.scopus.com/inward/record.url?scp=0036636836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036636836&partnerID=8YFLogxK

M3 - Article

C2 - 12066226

AN - SCOPUS:0036636836

VL - 9

SP - 879

EP - 885

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 4

ER -

Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Cite this